JP2022543702A5 - - Google Patents
Info
- Publication number
- JP2022543702A5 JP2022543702A5 JP2022508455A JP2022508455A JP2022543702A5 JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5 JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- seq
- binding domain
- receptor
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885093P | 2019-08-09 | 2019-08-09 | |
| US62/885,093 | 2019-08-09 | ||
| US202063005670P | 2020-04-06 | 2020-04-06 | |
| US63/005,670 | 2020-04-06 | ||
| PCT/US2020/045228 WO2021030149A1 (en) | 2019-08-09 | 2020-08-06 | Cell-surface receptors responsive to loss of heterozygosity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543702A JP2022543702A (ja) | 2022-10-13 |
| JP2022543702A5 true JP2022543702A5 (https=) | 2023-08-01 |
| JP7739261B2 JP7739261B2 (ja) | 2025-09-16 |
Family
ID=74571174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508455A Active JP7739261B2 (ja) | 2019-08-09 | 2020-08-06 | ヘテロ接合性の喪失に応答する細胞表面受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240173352A1 (https=) |
| EP (1) | EP4010377A4 (https=) |
| JP (1) | JP7739261B2 (https=) |
| KR (1) | KR20220053587A (https=) |
| CN (1) | CN114585645B (https=) |
| AU (1) | AU2020329881A1 (https=) |
| BR (1) | BR112022002465A2 (https=) |
| CA (1) | CA3150071A1 (https=) |
| IL (1) | IL290413A (https=) |
| MX (1) | MX2022001711A (https=) |
| WO (1) | WO2021030149A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| CN115052887B (zh) | 2019-12-11 | 2026-03-31 | A2生物治疗公司 | 基于lilrb1的嵌合抗原受体 |
| EP4107175A4 (en) * | 2020-02-20 | 2024-03-20 | Senti Biosciences, Inc. | ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS |
| EP4196493A1 (en) | 2020-08-13 | 2023-06-21 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
| WO2022040444A1 (en) * | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
| WO2022040470A1 (en) * | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| WO2022177979A1 (en) * | 2021-02-16 | 2022-08-25 | A2 Biotherapeutics, Inc. | Compositions and methods for treating her2 positive cancers |
| AU2022235103A1 (en) * | 2021-03-12 | 2023-09-21 | The Johns Hopkins University | Engineered immune cells and uses thereof |
| WO2023014633A2 (en) * | 2021-08-03 | 2023-02-09 | A2 Biotherapeutics, Inc. | Vector systems for delivery of two polynucleotides and methods of making and using same |
| AU2023213691A1 (en) * | 2022-01-28 | 2024-09-05 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| WO2023150698A2 (en) * | 2022-02-04 | 2023-08-10 | Nkilt Therapeutics, Inc. | Chimeric ilt receptor compositions and methods |
| WO2023172954A2 (en) * | 2022-03-08 | 2023-09-14 | A2 Biotherapeutics, Inc. | Engineered receptors specific to hla-e and methods of use |
| WO2023215183A1 (en) * | 2022-05-02 | 2023-11-09 | Tscan Therapeutics, Inc. | Multiplexed t cell receptor compositions, combination therapies, and uses thereof |
| WO2026006575A1 (en) * | 2024-06-26 | 2026-01-02 | A2 Biotherapeutics, Inc. | Immune cells with paired receptors and uses in treating autoimmunity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450285C (en) * | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US6894149B2 (en) * | 2001-10-11 | 2005-05-17 | Protein Design Labs, Inc. | Anti-HLA-DA antibodies and the methods of using thereof |
| WO2006031221A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2828290B1 (en) * | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| CN109843929B (zh) * | 2016-08-23 | 2024-07-05 | 加利福尼亚大学董事会 | 蛋白水解可切割的嵌合多肽及其使用方法 |
| CN109996868A (zh) * | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| BR112019006006A2 (pt) | 2016-09-28 | 2019-06-25 | Gavish-Galilee Bio Applications Ltd. | molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico. |
| US12378297B2 (en) * | 2017-04-14 | 2025-08-05 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| SG11202002520UA (en) * | 2017-09-19 | 2020-04-29 | Univ British Columbia | Anti-hla-a2 antibodies and methods of using the same |
| WO2019068007A1 (en) * | 2017-09-28 | 2019-04-04 | Immpact-Bio Ltd. | UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) |
| WO2019084055A1 (en) * | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| MA51184A (fr) * | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
| KR20210044736A (ko) * | 2018-05-03 | 2021-04-23 | 주노 쎄러퓨티크스 인코퍼레이티드 | 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법 |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| WO2021222576A1 (en) * | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
-
2020
- 2020-08-06 MX MX2022001711A patent/MX2022001711A/es unknown
- 2020-08-06 KR KR1020227007569A patent/KR20220053587A/ko active Pending
- 2020-08-06 BR BR112022002465A patent/BR112022002465A2/pt unknown
- 2020-08-06 CN CN202080068565.7A patent/CN114585645B/zh active Active
- 2020-08-06 US US17/633,358 patent/US20240173352A1/en active Pending
- 2020-08-06 WO PCT/US2020/045228 patent/WO2021030149A1/en not_active Ceased
- 2020-08-06 JP JP2022508455A patent/JP7739261B2/ja active Active
- 2020-08-06 EP EP20853234.1A patent/EP4010377A4/en active Pending
- 2020-08-06 AU AU2020329881A patent/AU2020329881A1/en active Pending
- 2020-08-06 CA CA3150071A patent/CA3150071A1/en active Pending
-
2022
- 2022-02-07 IL IL290413A patent/IL290413A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543702A5 (https=) | ||
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| Yousefi et al. | Immunotherapy of cancers comes of age | |
| JP2021526365A5 (https=) | ||
| ES2641870T3 (es) | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer | |
| Seyedin et al. | Strategies for combining immunotherapy with radiation for anticancer therapy | |
| KR102186180B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| Comoli et al. | Development of adaptive immune effector therapies in solid tumors | |
| Lettieri et al. | Progress and opportunities for immune therapeutics in osteosarcoma | |
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| Duarte et al. | Gastric cancer: basic aspects | |
| JP2023552998A5 (https=) | ||
| JP2021500406A5 (https=) | ||
| BR112018070741A2 (pt) | receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr | |
| JP2018513687A5 (https=) | ||
| JP2018520679A5 (https=) | ||
| JP2017535292A5 (https=) | ||
| JP2022537700A5 (https=) | ||
| Kim et al. | Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| JP2021501567A5 (https=) | ||
| Shi et al. | Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies | |
| Cruz-Ramos et al. | CAR-T cell and Personalized Medicine |